+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06686381

Evaluating Two Tetra-modality Bladder Preservation Strategies Using TURBT, Chemotherapy, Avelumab Immunotherapy, and Radiation Therapy in Muscle-invasive Bladder Cancer

Led by American University of Beirut Medical Center · Updated on 2026-10-29

80

Participants Needed

1

Research Sites

2 weeks

Total Duration

AI-Summary

What This Trial Is About

This trial is investigating treatments for muscle-invasive bladder cancer MIBC, an aggressive type of bladder cancer with a 5-year survival rate of about 40%. The study aims to assess the safety and effectiveness of adding the immunotherapy drug Avelumab to standard bladder preservation methods, comparing two multi-step treatment plans to increase the chance of keeping the bladder intact and reduce the need for bladder removal surgery. Both treatment strategies are designed to explore a combination of tumor removal, chemotherapy, radiation, and immunotherapy. Participants receive one of two treatment plans. Both start with maximum tumor removal through TURBT, followed by induction chemotherapy combined with Avelumab immunotherapy. After this, patients undergo radiation therapy. In one plan, patients continue with Avelumab maintenance every two weeks for 12 months. In the other plan, patients enter a watch-and-wait phase for one year instead of maintenance therapy. The total duration for these treatments can last up to two years from when participants join the study. Throughout the trial, participants undergo clinical evaluations including CT or MRI scans of the chest, abdomen, and pelvis, cystoscopy with biopsy, and urine cytology at four months after starting induction therapy. Quality of life and safety assessments are conducted regularly during treatment and follow-up. The main outcome measured is the proportion of patients who avoid bladder removal surgery two years after treatment begins. This study is sponsored by the American University of Beirut Medical Center and includes ongoing monitoring of response rates and adverse effects.

CONDITIONS

Brief Title

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

Research Team

A

Ali I. Shamseddine, MD, FRCP, ESCO

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here